Reaction
Blood Product Transfusion Dependent reporting signals
As of the last recalculation, Blood Product Transfusion Dependent appears in 419 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is ECULIZUMAB (PRR 115.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Eculizumab | 97 | 115.1 | 115.3 |
| Azacitidine | 49 | 92.8 | 92.9 |
| Azacitidine For | 21 | 60.3 | 60.4 |
| Deferasirox | 27 | 54.0 | 54.1 |
| Erythropoietin | 18 | 45.4 | 45.5 |
| Epoetin Alfa | 10 | 42.9 | 43.0 |
| Ruxolitinib | 29 | 21.5 | 21.5 |
| Axicabtagene Ciloleucel | 4 | 20.3 | 20.3 |
| Venetoclax | 23 | 19.6 | 19.6 |
| Blinatumomab | 3 | 14.4 | 14.4 |